MeSH term
Frequency | Condition_Probility | Research Support, Non-U.S. Gov't | 391 | 0.0 |
Calcium/*metabolism | 4 | 0.0 |
Cell Division/drug effects/immunology | 3 | 4.0 |
Humans | 760 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Tumor Cells, Cultured | 45 | 0.0 |
*Leukemic Infiltration | 3 | 27.0 |
Male | 358 | 0.0 |
Polymerase Chain Reaction | 23 | 0.0 |
Skin/*pathology | 3 | 3.0 |
Cyclophosphamide/administration & dosage | 4 | 1.0 |
DNA, Neoplasm/analysis | 13 | 1.0 |
Doxorubicin/administration & dosage | 5 | 2.0 |
Fatal Outcome | 22 | 3.0 |
Flow Cytometry | 130 | 2.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/genetics | 4 | 33.0 |
Killer Cells, Natural/*pathology | 7 | 24.0 |
Prednisone/administration & dosage | 6 | 7.0 |
RNA, Viral/analysis | 2 | 0.0 |
Tumor Markers, Biological/analysis | 13 | 1.0 |
Vincristine/administration & dosage | 7 | 4.0 |
Cell Division/drug effects | 19 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 6 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 5 | 1.0 |
Interleukin-3/pharmacology | 6 | 2.0 |
Karyotyping | 75 | 4.0 |
Middle Aged | 245 | 0.0 |
*Transcription Factors | 8 | 0.0 |
Immunophenotyping | 222 | 7.0 |
Prognosis | 66 | 1.0 |
Retrospective Studies | 17 | 0.0 |
Animals | 63 | 0.0 |
Antigens, CD/biosynthesis | 6 | 1.0 |
*Cell Differentiation | 2 | 0.0 |
English Abstract | 71 | 0.0 |
Hematopoietic Stem Cell Transplantation | 3 | 1.0 |
Hematopoietic Stem Cells/*cytology/metabolism | 2 | 8.0 |
Transplantation, Heterologous | 3 | 0.0 |
Acute Disease | 89 | 3.0 |
Child, Preschool | 66 | 0.0 |
Combined Modality Therapy | 11 | 0.0 |
Fetal Blood | 2 | 1.0 |
Remission Induction | 31 | 5.0 |
Biopsy, Needle | 3 | 0.0 |
Female | 293 | 0.0 |
Receptors, Antigen, T-Cell, gamma-delta/*metabolism | 2 | 12.0 |
Biological Markers/analysis | 7 | 0.0 |
Bone Marrow Cells/*chemistry | 2 | 16.0 |
Case-Control Studies | 5 | 0.0 |
Leukemia, Myeloid, Chronic/immunology | 2 | 40.0 |
Membrane Glycoproteins/*analysis | 3 | 2.0 |
Adolescent | 145 | 0.0 |
Adult | 283 | 0.0 |
Aged | 188 | 0.0 |
Antigens, CD34/analysis | 7 | 1.0 |
Antigens, Differentiation/analysis | 23 | 7.0 |
Bone Marrow/pathology | 24 | 6.0 |
Cell Differentiation/drug effects | 13 | 1.0 |
Cell Lineage | 11 | 2.0 |
In Situ Hybridization, Fluorescence | 12 | 0.0 |
Leukemia, Lymphocytic, Acute/*pathology | 2 | 10.0 |
Philadelphia Chromosome | 5 | 11.0 |
T-Lymphocyte Subsets/immunology | 5 | 1.0 |
Chronic Disease | 5 | 0.0 |
Mutation | 2 | 0.0 |
Antibodies, Neoplasm/immunology | 2 | 5.0 |
Antigens, CD7/biosynthesis/*immunology | 2 | 100.0 |
Immunoenzyme Techniques | 18 | 0.0 |
Lymphocytes/*immunology | 6 | 1.0 |
Paraffin Embedding | 3 | 1.0 |
Predictive Value of Tests | 4 | 0.0 |
Antigens, CD/analysis | 79 | 4.0 |
Antigens, CD3/analysis | 9 | 3.0 |
Antigens, CD56/*analysis | 8 | 25.0 |
Biological Markers | 11 | 0.0 |
Cytoplasm/immunology | 7 | 7.0 |
Killer Cells, Natural/*immunology | 8 | 1.0 |
Receptors, Immunologic/*analysis | 2 | 3.0 |
T-Lymphocytes/*immunology | 50 | 2.0 |
Antigens, CD45/analysis | 11 | 4.0 |
Antigens, Differentiation/*analysis | 8 | 4.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 32 | 9.0 |
Cell Adhesion Molecules/analysis | 6 | 3.0 |
Cell Differentiation | 42 | 1.0 |
Lymphocyte Activation | 30 | 0.0 |
Receptors, Immunologic/analysis | 3 | 3.0 |
Aged, 80 and over | 63 | 0.0 |
Infusions, Intravenous | 3 | 0.0 |
Survival Rate | 17 | 0.0 |
Time Factors | 14 | 0.0 |
Antigens, CD7/*immunology | 14 | 93.0 |
Antigens, Neoplasm/immunology | 5 | 3.0 |
Fluorescent Antibody Technique | 29 | 1.0 |
Immunohistochemistry | 56 | 0.0 |
Lymphoma, T-Cell/immunology/pathology | 2 | 50.0 |
Mice | 45 | 0.0 |
Mice, Inbred BALB C | 10 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Antigens, CD3 | 13 | 2.0 |
Antigens, CD30 | 2 | 7.0 |
Antigens, CD56 | 4 | 5.0 |
Antigens, CD8 | 3 | 1.0 |
Killer Cells, Natural/immunology/*pathology | 2 | 15.0 |
Lymph Nodes/pathology | 9 | 3.0 |
Bone Marrow Transplantation | 9 | 3.0 |
Daunorubicin/administration & dosage | 10 | 27.0 |
Disease Progression | 8 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 15 | 19.0 |
Genes, Immunoglobulin | 10 | 5.0 |
Glycophorin/analysis | 2 | 14.0 |
HLA-DR Antigens/analysis | 22 | 3.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Neoplasm Proteins/*analysis | 6 | 1.0 |
Peroxidase/analysis | 8 | 12.0 |
Prednisolone/administration & dosage | 5 | 7.0 |
Recurrence | 10 | 0.0 |
Transplantation, Homologous | 4 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 2 | 4.0 |
P-Glycoprotein/biosynthesis/genetics/*physiology | 2 | 100.0 |
Prospective Studies | 10 | 0.0 |
Survival Analysis | 15 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Verapamil/pharmacology | 2 | 2.0 |
Comparative Study | 59 | 0.0 |
Leukocyte Count | 15 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Chromosome Aberrations | 23 | 4.0 |
Disease-Free Survival | 6 | 0.0 |
Inversion, Chromosome | 2 | 3.0 |
Translocation, Genetic | 13 | 1.0 |
Antigens, CD/metabolism | 15 | 1.0 |
Cytogenetic Analysis | 6 | 4.0 |
Gene Rearrangement, T-Lymphocyte | 17 | 16.0 |
In Vitro | 16 | 0.0 |
Mice, SCID | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
*Tumor Cells, Cultured | 5 | 7.0 |
Antigens, CD3/metabolism | 2 | 1.0 |
Antigens, CD7/metabolism | 5 | 100.0 |
Apoptosis/*physiology | 2 | 0.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Cytokines/secretion | 2 | 2.0 |
Rats | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Antigens, CD7/*metabolism | 9 | 90.0 |
Chromosomes, Human, Pair 21 | 4 | 3.0 |
Chromosomes, Human, Pair 8 | 3 | 2.0 |
Gene Rearrangement | 24 | 5.0 |
Leukemia, Myelocytic, Acute/genetics/immunology/*pathology | 3 | 50.0 |
Oncogene Proteins, Fusion/*genetics | 2 | 1.0 |
*Polyploidy | 2 | 7.0 |
RNA, Messenger/analysis | 13 | 0.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
*Chromosomes, Human, Pair 11 | 7 | 1.0 |
*Chromosomes, Human, Pair 14 | 3 | 1.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
*Translocation, Genetic | 15 | 1.0 |
Antibodies, Monoclonal/*immunology | 8 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Antigens, CD3/biosynthesis | 2 | 3.0 |
Antigens, CD4/biosynthesis | 4 | 4.0 |
Antigens, CD7/biosynthesis | 2 | 50.0 |
Antigens, CD8/biosynthesis | 4 | 11.0 |
Blotting, Southern | 24 | 0.0 |
*Chromosome Aberrations | 14 | 2.0 |
*Chromosome Deletion | 3 | 0.0 |
*Chromosomes, Human, Pair 13 | 2 | 1.0 |
*Chromosomes, Human, Pair 3 | 2 | 0.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
Gene Deletion | 3 | 0.0 |
Gene Duplication | 2 | 1.0 |
Herpesvirus 4, Human/genetics | 5 | 7.0 |
Killer Cells, Natural/*cytology | 7 | 30.0 |
Leukemia/*genetics | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols | 2 | 6.0 |
Diagnosis, Differential | 21 | 0.0 |
Gene Rearrangement, B-Lymphocyte | 2 | 3.0 |
Leukemia, Myelocytic, Acute/*immunology | 10 | 29.0 |
P-Glycoprotein/*metabolism | 2 | 2.0 |
Antigens, CD2/analysis | 9 | 22.0 |
Antigens, CD4/analysis | 10 | 2.0 |
Antigens, CD5/analysis | 5 | 11.0 |
Antigens, CD7/analysis | 14 | 73.0 |
Antigens, CD8/analysis | 3 | 1.0 |
*Flow Cytometry | 11 | 6.0 |
*Immunophenotyping | 22 | 12.0 |
Receptors, Antigen, T-Cell/analysis | 6 | 5.0 |
Antigens, CD56/analysis | 5 | 7.0 |
Drug Synergism | 3 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics | 2 | 28.0 |
Genotype | 16 | 0.0 |
Interleukin-2/pharmacology | 11 | 1.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis/genetics | 2 | 50.0 |
Stem Cell Factor/pharmacology | 3 | 2.0 |
Tumor Cells, Cultured/*cytology | 2 | 13.0 |
Antigens, CD/immunology | 16 | 3.0 |
Child | 110 | 0.0 |
Leukemia, Lymphocytic, Acute/*immunology | 6 | 22.0 |
Antigens, CD7/*analysis | 19 | 76.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 33 | 6.0 |
Cytarabine/administration & dosage | 15 | 17.0 |
Leukemia, Myelocytic, Acute/*diagnosis/pathology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/*immunology | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 90 | 0.0 |
Antigens, Neoplasm/analysis | 22 | 6.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/*cytology/immunology | 2 | 22.0 |
CD8-Positive T-Lymphocytes/*immunology | 3 | 0.0 |
Eosinophils/immunology | 2 | 3.0 |
Infant | 35 | 0.0 |
Lymphocyte Subsets/immunology | 3 | 2.0 |
Radioimmunoassay | 3 | 0.0 |
Antibodies, Monoclonal | 42 | 1.0 |
Antigens, CD/*analysis | 74 | 9.0 |
Antigens, CD13/analysis | 2 | 8.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 4 | 3.0 |
Antigens, Neoplasm/*analysis | 21 | 5.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Phenotype | 94 | 1.0 |
Bone Marrow Cells/immunology/pathology | 2 | 14.0 |
Cohort Studies | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 22 | 2.0 |
DNA Primers | 4 | 0.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/*genetics | 3 | 60.0 |
Sensitivity and Specificity | 5 | 0.0 |
Antigens, CD/*metabolism | 10 | 1.0 |
CD4-Positive T-Lymphocytes/*metabolism | 3 | 3.0 |
Receptors, Antigen, T-Cell/chemistry/*metabolism | 2 | 15.0 |
*T-Lymphocyte Subsets | 3 | 4.0 |
HLA-D Antigens/analysis | 3 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 8 | 1.0 |
Treatment Outcome | 16 | 0.0 |
Antigens, CD7/blood | 4 | 80.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
ADP-ribosyl Cyclase | 12 | 2.0 |
*Antigens, CD | 15 | 1.0 |
B-Lymphocytes/cytology | 3 | 3.0 |
Fetal Blood/*cytology/immunology | 4 | 17.0 |
Hematopoiesis | 4 | 1.0 |
Hematopoietic Stem Cells/*cytology/immunology | 6 | 7.0 |
Lymphocyte Subsets/*immunology | 5 | 3.0 |
Lymphocytes/cytology | 3 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 2 | 6.0 |
Antigens/*immunology | 2 | 2.0 |
*Chromosomes, Human, Pair 17 | 5 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Fusion Proteins, bcr-abl/genetics | 3 | 7.0 |
*Proto-Oncogenes | 7 | 1.0 |
Age Factors | 6 | 0.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
DNA, Viral/analysis | 5 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 8 | 5.0 |
*Chromosomes, Human, Pair 10 | 5 | 2.0 |
T-Lymphocytes/immunology/pathology | 7 | 11.0 |
*Trisomy | 8 | 7.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Killer Cells, Natural/immunology | 8 | 1.0 |
Neprilysin/analysis | 4 | 7.0 |
*Phenotype | 3 | 1.0 |
B-Lymphocytes/immunology | 7 | 0.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 8 | 24.0 |
*Antigens, CD7 | 4 | 100.0 |
Cell Division | 28 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Transfection | 13 | 0.0 |
Antigens, CD2/analysis/genetics | 2 | 66.0 |
Antigens, CD4/analysis/genetics | 2 | 18.0 |
Antigens, CD7/analysis/genetics | 2 | 100.0 |
Antigens, CD8/analysis/genetics | 2 | 50.0 |
Gene Expression Regulation | 5 | 0.0 |
Lymph Nodes/immunology | 3 | 3.0 |
Molecular Weight | 4 | 0.0 |
T-Lymphocytes/immunology | 22 | 1.0 |
T-Lymphocytes, Cytotoxic/immunology | 5 | 1.0 |
Antigens, CD4/*analysis | 5 | 3.0 |
Clone Cells | 10 | 0.0 |
Genes, T-Cell Receptor gamma | 2 | 66.0 |
Sezary Syndrome/*immunology | 2 | 40.0 |
Antibody Formation | 2 | 0.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Disease Models, Animal | 2 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
*N-Glycosyl Hydrolases | 6 | 10.0 |
Bone Marrow Cells/*immunology | 2 | 7.0 |
Leukemia/immunology/*pathology | 2 | 25.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
CD4-Positive T-Lymphocytes/immunology | 9 | 1.0 |
Cells, Cultured | 35 | 0.0 |
Jurkat Cells | 10 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Signal Transduction | 10 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
Antigens, CD7/*biosynthesis | 5 | 100.0 |
Receptors, Interleukin-2/analysis | 3 | 1.0 |
Skin Neoplasms/immunology/*pathology | 3 | 11.0 |
Apoptosis/drug effects | 2 | 0.0 |
Infant, Newborn | 19 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Immunophenotyping/*methods | 6 | 8.0 |
Lymphoma, T-Cell/*pathology | 2 | 14.0 |
Testicular Neoplasms/*pathology | 2 | 14.0 |
Antigens, Surface/analysis | 23 | 5.0 |
Blotting, Western | 8 | 0.0 |
Bone Marrow | 2 | 5.0 |
Etoposide/therapeutic use | 3 | 16.0 |
Interferon Type II/physiology | 3 | 3.0 |
Japan | 2 | 0.0 |
Killer Cells, Natural/chemistry/*pathology | 3 | 50.0 |
Neoplasm Proteins/analysis | 4 | 1.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Vincristine/therapeutic use | 2 | 5.0 |
Blood Platelets/immunology | 2 | 2.0 |
Aging/*immunology | 2 | 1.0 |
Immunologic Memory | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology | 9 | 1.0 |
Adjuvants, Immunologic/*physiology | 3 | 9.0 |
Antigens, CD7/*physiology | 4 | 100.0 |
Apoptosis/*immunology | 3 | 1.0 |
Cell Line | 28 | 0.0 |
Galectin 1 | 2 | 25.0 |
Signal Transduction/*immunology | 3 | 0.0 |
T-Lymphocytes/*cytology/*immunology | 2 | 11.0 |
*Chromosomes, Human, Pair 4 | 4 | 1.0 |
Leukemia, T-Cell, Acute/*genetics | 2 | 5.0 |
Antigens, CD14/analysis | 3 | 2.0 |
Bone Marrow Cells/*cytology | 2 | 4.0 |
Coculture Techniques | 3 | 0.0 |
Antigens/*analysis | 3 | 3.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Cytogenetics | 4 | 4.0 |
Biopsy | 16 | 0.0 |
Antigens, CD3/*analysis | 3 | 10.0 |
Antibodies, Monoclonal/therapeutic use | 6 | 3.0 |
Antigens, CD7/immunology | 3 | 75.0 |
*Hematopoietic Stem Cell Transplantation | 4 | 1.0 |
Reference Values | 6 | 0.0 |
Immunity, Cellular | 5 | 0.0 |
Immunoglobulins/analysis | 4 | 1.0 |
Quality Control | 2 | 1.0 |
Antigens, CD34/*analysis | 6 | 2.0 |
Cell Separation/methods | 4 | 2.0 |
Antigens, CD/analysis/immunology | 2 | 4.0 |
Antigens, CD3/analysis/immunology | 2 | 16.0 |
Antigens, CD4/analysis/immunology | 2 | 16.0 |
Antigens, CD7/analysis/immunology | 2 | 100.0 |
Antigens, Surface/*analysis | 15 | 7.0 |
Apoptosis | 3 | 0.0 |
Flow Cytometry/*methods | 11 | 4.0 |
DNA Nucleotidylexotransferase/*biosynthesis | 2 | 66.0 |
Flow Cytometry/methods | 6 | 2.0 |
Leukemia, Myelocytic, Acute/drug therapy/*immunology | 3 | 75.0 |
*Neoplasm Proteins | 2 | 0.0 |
Hematopoietic Stem Cells/*immunology | 8 | 5.0 |
NAD+ Nucleosidase/analysis | 3 | 6.0 |
Amino Acid Sequence | 9 | 0.0 |
Base Sequence | 30 | 0.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Molecular Sequence Data | 34 | 0.0 |
Lymphocyte Count | 9 | 1.0 |
Lymphocyte Subsets/*cytology | 2 | 8.0 |
T-Lymphocytes, Helper-Inducer/immunology | 3 | 1.0 |
HIV-1/*physiology | 3 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Antigens, CD34/*immunology | 4 | 5.0 |
Cell Differentiation/immunology | 11 | 3.0 |
Skin/pathology | 4 | 1.0 |
Chromosome Mapping | 5 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
T-Lymphocytes/*metabolism | 4 | 1.0 |
Cell Adhesion | 7 | 0.0 |
Cell Movement | 2 | 0.0 |
Fibronectins/*metabolism | 2 | 2.0 |
T-Lymphocytes/*physiology | 4 | 1.0 |
Antigens, CD/blood | 3 | 1.0 |
Antigens, CD34/*blood/immunology | 2 | 66.0 |
Cell Separation | 20 | 1.0 |
Immunomagnetic Separation/methods | 2 | 18.0 |
Leukapheresis | 6 | 5.0 |
Leukocytes, Mononuclear/immunology | 5 | 1.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Chromosome Banding | 10 | 1.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
DNA Primers/chemistry | 4 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/*genetics | 4 | 44.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 6 | 8.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics | 5 | 20.0 |
Protein Conformation | 4 | 0.0 |
Cell Differentiation/physiology | 5 | 1.0 |
Leukemia, Myeloid/genetics/*pathology | 3 | 25.0 |
Taiwan | 2 | 1.0 |
Antigens, CD26/analysis | 2 | 33.0 |
*Lymphocyte Activation | 13 | 0.0 |
Lymphoma, T-Cell, Cutaneous/*immunology | 2 | 66.0 |
Sezary Syndrome/immunology | 2 | 33.0 |
Skin Neoplasms/*immunology | 6 | 16.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 7 | 3.0 |
Pregnancy | 10 | 0.0 |
Antigens, CD/*biosynthesis | 7 | 3.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 2 | 4.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 8 | 12.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Receptors, Antigen, T-Cell/genetics | 11 | 13.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Cell Line, Transformed | 3 | 0.0 |
Signal Transduction/immunology | 4 | 1.0 |
Cytokines/pharmacology | 9 | 2.0 |
Enzyme Activation | 5 | 0.0 |
CD4-CD8 Ratio | 6 | 0.0 |
Cytokines/biosynthesis/drug effects | 2 | 15.0 |
Interferon Type II/biosynthesis | 3 | 0.0 |
Antigens, Surface/immunology | 8 | 4.0 |
Cell Size | 2 | 0.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 3 | 23.0 |
Antigens, CD8/analysis/immunology | 2 | 22.0 |
Cytotoxicity Tests, Immunologic | 5 | 1.0 |
Tumor Cells, Cultured/immunology | 3 | 3.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 10 | 2.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Antigens, CD56/*metabolism | 3 | 21.0 |
B-Lymphocytes/immunology/pathology | 3 | 6.0 |
DNA Primers/genetics | 2 | 0.0 |
*Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 3 | 50.0 |
Killer Cells, Natural/immunology/pathology | 2 | 13.0 |
Lymphoma/*genetics/*immunology/pathology | 2 | 100.0 |
Tumor Stem Cells/*immunology/pathology | 2 | 40.0 |
HLA-DR Antigens/analysis/immunology | 2 | 10.0 |
Phytohemagglutinins | 5 | 5.0 |
Blast Crisis | 3 | 8.0 |
Immunomagnetic Separation | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 18 | 1.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
HL-60 Cells | 2 | 0.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Analysis of Variance | 2 | 0.0 |
DNA Nucleotidylexotransferase/*analysis | 4 | 40.0 |
Leukemia, Myeloid/*metabolism | 3 | 9.0 |
Risk Factors | 6 | 0.0 |
P-Glycoprotein/*biosynthesis | 2 | 6.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Cytarabine/therapeutic use | 4 | 10.0 |
Leukemia, Myeloid/drug therapy/metabolism/*pathology | 2 | 100.0 |
Microscopy, Electron | 15 | 0.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Interleukin-2/*therapeutic use | 2 | 1.0 |
Leukemia, Myeloid/*genetics/immunology | 3 | 50.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
*Bone Marrow Transplantation | 9 | 2.0 |
HLA Antigens/immunology | 3 | 1.0 |
Histocompatibility Testing | 2 | 0.0 |
*Lymphocyte Depletion | 3 | 3.0 |
Rabbits | 4 | 0.0 |
Antigens, CD/*physiology | 9 | 2.0 |
Antigens, CD3/physiology | 2 | 2.0 |
Carrier Proteins/*physiology | 3 | 1.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Receptors, Antigen, T-Cell/physiology | 3 | 2.0 |
Receptors, IgG/physiology | 2 | 5.0 |
Neprilysin/*metabolism | 2 | 14.0 |
Leukemia, Myeloid/*immunology/pathology | 3 | 21.0 |
Antigens, CD/*analysis/genetics | 3 | 12.0 |
Leukemia, Lymphocytic, Acute/enzymology/pathology | 2 | 66.0 |
Tumor Stem Cells/enzymology | 2 | 25.0 |
Follow-Up Studies | 11 | 0.0 |
Antigens, CD7 | 98 | 85.0 |
False Positive Reactions | 3 | 1.0 |
Leukemia, Myelocytic, Acute/*pathology | 4 | 10.0 |
Lymphocytes/pathology | 2 | 2.0 |
Blast Crisis/*pathology | 3 | 16.0 |
Leukemia, Myeloid, Philadelphia-Positive/*pathology | 3 | 33.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
Histocytochemistry | 11 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 8 | 4.0 |
Tumor Markers, Biological/*analysis | 15 | 1.0 |
Killer Cells, Natural/*cytology/immunology | 3 | 42.0 |
Kinetics | 8 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Stem Cells/cytology/*immunology | 2 | 28.0 |
Hematopoietic Stem Cells/immunology/pathology | 3 | 16.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
*Antibodies, Monoclonal | 4 | 1.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Hybridomas/immunology | 2 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Leukemia, T-Cell, Acute/*immunology | 3 | 27.0 |
Bone Marrow/*pathology | 8 | 5.0 |
Hematopoietic Stem Cells/pathology | 2 | 5.0 |
Leukemia, Myeloid/pathology | 2 | 9.0 |
Cell Cycle | 5 | 0.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
Multivariate Analysis | 5 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
Fluorescein-5-isothiocyanate | 4 | 2.0 |
Fluorescent Dyes | 3 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Phycoerythrin | 3 | 15.0 |
*Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 4 | 33.0 |
Leukemia, Myelocytic, Acute/*metabolism | 2 | 11.0 |
Antigens, CD34/metabolism | 2 | 0.0 |
Blotting, Northern | 7 | 0.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
*Receptors, Cytokine | 2 | 1.0 |
Antigens, CD7/*blood | 2 | 66.0 |
Thioguanine/administration & dosage | 4 | 44.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Leukemia, Myeloid/*immunology | 5 | 12.0 |
Cytotoxicity, Immunologic | 17 | 1.0 |
In Situ Hybridization | 5 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Leukemia, Myelocytic, Acute/genetics/*pathology | 2 | 25.0 |
Antigens, Neoplasm/*blood | 2 | 4.0 |
Fetal Blood/*cytology | 5 | 2.0 |
Cell Count | 5 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Spleen/cytology/immunology | 2 | 3.0 |
Thymus Gland/cytology/immunology | 3 | 7.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Leukemia/*diagnosis | 2 | 20.0 |
Chromosome Disorders | 14 | 4.0 |
HLA Antigens/analysis | 2 | 0.0 |
Leukemia, Monocytic, Acute/classification | 2 | 100.0 |
Leukemia, Myelocytic, Acute/classification | 2 | 100.0 |
Leukemia, Myeloid/*classification | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 39 | 18.0 |
Intestinal Mucosa/cytology/*immunology | 2 | 13.0 |
T-Lymphocytes/classification/*immunology | 4 | 6.0 |
Receptors, Interleukin-2/*metabolism | 2 | 2.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
DNA Fragmentation | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
*Membrane Glycoproteins | 3 | 0.0 |
B-Lymphocytes/*pathology | 2 | 4.0 |
Leukemia, Lymphocytic/*pathology | 2 | 10.0 |
T-Lymphocytes/*pathology | 5 | 7.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Leukocytes/*immunology | 4 | 2.0 |
Antigens, CD/*blood | 6 | 3.0 |
Bone Marrow/immunology | 6 | 4.0 |
Isoantigens/immunology | 4 | 4.0 |
Lymphocyte Subsets | 3 | 1.0 |
Mitogens/pharmacology | 2 | 0.0 |
Erythropoiesis | 2 | 2.0 |
Leukopoiesis | 2 | 16.0 |
Liver/*embryology | 2 | 13.0 |
Leukemia, Myelocytic, Acute/*genetics/immunology | 2 | 33.0 |
Daunorubicin/therapeutic use | 2 | 14.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 2 | 6.0 |
Clinical Trials | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Peroxidase/*analysis | 3 | 15.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 3 | 2.0 |
Ionomycin/pharmacology | 3 | 1.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Drug Administration Schedule | 3 | 0.0 |
Antigens, CD3/genetics | 2 | 14.0 |
Chromosome Aberrations/pathology | 3 | 33.0 |
Gene Expression | 12 | 0.0 |
Leukemia/*pathology | 2 | 4.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Cell Adhesion/immunology | 3 | 1.0 |
Phosphorylation | 7 | 0.0 |
T-Lymphocytes/*immunology/pathology | 3 | 5.0 |
Tyrosine/metabolism | 2 | 0.0 |
Antigens, CD4/*physiology | 2 | 1.0 |
*Immunologic Memory | 3 | 2.0 |
T-Lymphocytes/*cytology/immunology | 4 | 8.0 |
Genetic Markers | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
*Inversion, Chromosome | 2 | 2.0 |
Leukemia, Myelocytic, Acute/*genetics/immunology/pathology | 2 | 66.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Binding Sites, Antibody | 5 | 1.0 |
Cell Transformation, Neoplastic/pathology | 2 | 4.0 |
Antigens, CD/*analysis/immunology | 2 | 6.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
Antibodies, Monoclonal/*therapeutic use | 8 | 2.0 |
Antigens, CD4/immunology | 3 | 1.0 |
*Immunotherapy | 2 | 1.0 |
*Hematopoiesis | 5 | 2.0 |
Hematopoietic Stem Cells/*cytology | 3 | 1.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
Chromosomes, Human, Pair 9 | 3 | 1.0 |
T-Lymphocytes/pathology | 5 | 4.0 |
Chimeric Proteins/therapeutic use | 2 | 16.0 |
*Immunosuppression | 2 | 2.0 |
Muromonab-CD3/therapeutic use | 2 | 15.0 |
Blast Crisis/*immunology | 3 | 75.0 |
Leukemia, Myeloid, Chronic/*immunology/*pathology | 2 | 100.0 |
*Renal Dialysis | 2 | 0.0 |
Antigens, Neoplasm/*metabolism | 3 | 3.0 |
Antigens, Surface/*metabolism | 3 | 5.0 |
*Gene Expression Regulation, Leukemic | 2 | 2.0 |
P-Glycoprotein/genetics/*metabolism | 2 | 10.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 5 | 18.0 |
Antigens, CD45/*analysis | 2 | 4.0 |
T-Lymphocyte Subsets/*metabolism | 2 | 6.0 |
Cell Line, Tumor | 3 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics | 5 | 4.0 |
T-Lymphocytes/*ultrastructure | 3 | 50.0 |
Colony-Forming Units Assay | 8 | 1.0 |
Interleukin-2/*pharmacology | 4 | 1.0 |
Point Mutation | 2 | 0.0 |
Lymphocyte Activation/immunology | 9 | 1.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Fetal Blood/cytology/immunology | 2 | 5.0 |
Hematopoietic Stem Cells/*cytology/*immunology | 2 | 8.0 |
Leukemia, T-Cell, Acute/*therapy | 2 | 100.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Transplantation | 4 | 0.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Immunotherapy | 3 | 0.0 |
Antigens, CD/*immunology | 10 | 2.0 |
Ligands | 3 | 0.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
*Bone Marrow Cells | 12 | 4.0 |
Cell Compartmentation | 2 | 0.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Macromolecular Substances | 3 | 0.0 |
Blood Cell Count | 3 | 1.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Epithelial Cells | 3 | 0.0 |
Phytohemagglutinins/pharmacology | 8 | 1.0 |
Gestational Age | 5 | 0.0 |
Hematopoietic Stem Cells/metabolism | 2 | 1.0 |
Liver/embryology | 2 | 6.0 |
6-Mercaptopurine/administration & dosage | 2 | 10.0 |
DNA Mutational Analysis | 3 | 0.0 |
Etoposide/administration & dosage | 5 | 4.0 |
HLA-DR Antigens/*analysis | 6 | 3.0 |
Mitoxantrone/administration & dosage | 3 | 11.0 |
Antigens, CD34/*biosynthesis | 2 | 4.0 |
Leukemia, Myelocytic, Acute/*pathology/physiopathology | 2 | 100.0 |
Tumor Stem Cells/*metabolism | 2 | 13.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
*Aging | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Leukemia, Nonlymphocytic, Acute/*genetics | 4 | 50.0 |
Antigens, CD2/metabolism | 2 | 7.0 |
Antigens, CD4/metabolism | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 9 | 7.0 |
Protein Biosynthesis | 3 | 0.0 |
Killer Cells, Natural/*immunology/pathology | 2 | 16.0 |
Receptors, Antigen, T-Cell/*genetics | 13 | 13.0 |
T-Lymphocytes/*immunology/metabolism | 3 | 1.0 |
Antigens, CD3/*metabolism | 2 | 4.0 |
Fetal Blood/cytology/*immunology | 2 | 10.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
Recombination, Genetic | 2 | 0.0 |
T-Lymphocytes/cytology/*immunology | 5 | 3.0 |
Antigens, CD34/biosynthesis | 3 | 3.0 |
Hematopoietic Stem Cells/immunology | 6 | 7.0 |
Thymus Gland/immunology/*pathology | 2 | 25.0 |
*Aneuploidy | 2 | 2.0 |
Chromosome Deletion | 5 | 0.0 |
Transplantation, Autologous | 5 | 1.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
DNA Probes | 4 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Life Tables | 3 | 1.0 |
Bone Marrow Cells | 21 | 4.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Leukemia/genetics/*pathology | 2 | 28.0 |
DNA, Neoplasm/genetics | 6 | 0.0 |
Splenic Neoplasms/pathology | 2 | 66.0 |
Cysteine/chemistry | 2 | 1.0 |
Skin Neoplasms/*immunology/pathology | 3 | 15.0 |
Antibodies, Monoclonal/immunology | 30 | 1.0 |
Antigens, Surface/blood | 3 | 13.0 |
Stem Cells/*immunology | 2 | 9.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/*genetics/immunology | 2 | 33.0 |
Trisomy | 2 | 1.0 |
HIV-1/*immunology | 4 | 0.0 |
T-Lymphocyte Subsets/*immunology/pathology | 3 | 14.0 |
Bone Marrow/*immunology | 4 | 6.0 |
*Lectins | 3 | 1.0 |
Mast Cells/*immunology | 2 | 7.0 |
Drug Carriers | 3 | 2.0 |
Thymidine/metabolism | 3 | 0.0 |
Antigens, CD | 4 | 3.0 |
Antigens, CD19 | 8 | 4.0 |
Antigens, CD2 | 9 | 1.0 |
Antigens, CD34 | 19 | 3.0 |
Hematopoietic Stem Cells/immunology/*physiology | 2 | 13.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 2 | 3.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Tumor Stem Cell Assay | 7 | 3.0 |
Calcium/metabolism | 5 | 0.0 |
Cell Nucleus/ultrastructure | 3 | 2.0 |
Cytokines/metabolism | 2 | 0.0 |
Human T-lymphotropic virus 1/genetics | 2 | 13.0 |
Leukemia, Myeloid, Chronic/*pathology | 2 | 9.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
T-Lymphocytes/*cytology | 4 | 4.0 |
Leukemia, Megakaryocytic, Acute/*pathology | 2 | 25.0 |
Lymphoma, T-Cell/pathology | 2 | 13.0 |
Genetic Vectors | 4 | 0.0 |
Lymphocyte Culture Test, Mixed | 4 | 0.0 |
Blast Crisis/pathology | 3 | 30.0 |
Lymphocyte Subsets/metabolism | 2 | 10.0 |
Tumor Markers, Biological | 2 | 0.0 |
*Immunoenzyme Techniques | 3 | 2.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 2 | 3.0 |
Bone Marrow/immunology/pathology | 3 | 8.0 |
Antigens, Differentiation/immunology | 4 | 3.0 |
*Immunotoxins | 2 | 16.0 |
Leukemia, T-Cell, Acute/*drug therapy/immunology | 2 | 66.0 |
Leukemia/*immunology | 2 | 5.0 |
Immunohistochemistry/*methods | 3 | 3.0 |
Antigens, CD4/physiology | 2 | 2.0 |
Lymphocyte Activation/*drug effects | 3 | 0.0 |
Antigens, CD59 | 2 | 1.0 |
Thymus Gland/immunology | 2 | 3.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Mycosis Fungoides/*immunology | 2 | 25.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Fetus/cytology | 2 | 3.0 |
Liver/cytology/*embryology | 2 | 20.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Cytokines/biosynthesis | 3 | 0.0 |
Phosphotyrosine | 3 | 1.0 |
Aneuploidy | 2 | 1.0 |
Hematopoietic Cell Growth Factors/pharmacology | 2 | 2.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/*pathology | 2 | 22.0 |
Tumor Stem Cells/chemistry/drug effects/*pathology | 2 | 100.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology | 2 | 33.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Antigens, CD28/physiology | 2 | 2.0 |
Antigens, CD5 | 10 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 3 | 3.0 |
Clone Cells/immunology | 3 | 1.0 |
Blood Platelets/cytology | 2 | 8.0 |
*Cell Line | 2 | 4.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Megakaryocytes/*cytology | 2 | 3.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Binding, Competitive | 6 | 0.0 |
Cell Separation/*methods | 5 | 3.0 |
*T-Lymphocytes | 4 | 8.0 |
Virus Replication | 2 | 0.0 |
Leukemia, Nonlymphocytic, Acute/*immunology | 2 | 25.0 |
Sex Factors | 3 | 0.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
*Gene Rearrangement | 6 | 2.0 |
Egtazic Acid/pharmacology | 3 | 2.0 |
Quinones/pharmacology | 2 | 1.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 6 | 4.0 |
Cell Adhesion/drug effects | 3 | 0.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Antigens, CD20 | 3 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 6 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/*blood | 2 | 13.0 |
Antigens, CD/*analysis/blood | 3 | 21.0 |
DNA/analysis | 2 | 0.0 |
Bone Marrow Examination | 3 | 8.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
DNA Nucleotidylexotransferase/analysis | 4 | 20.0 |
Killer Cells, Lymphokine-Activated/*immunology | 2 | 2.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 2 | 5.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
Leukemia, T-Cell, Acute/diagnosis/*immunology/pathology | 2 | 100.0 |
Software | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*immunology/mortality | 2 | 50.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*physiology | 2 | 9.0 |
Cell Fusion | 2 | 0.0 |
Cross Reactions | 2 | 0.0 |
Cytopathogenic Effect, Viral | 3 | 2.0 |
Epitopes | 3 | 0.0 |
CD4-Positive T-Lymphocytes/pathology | 2 | 2.0 |
T-Lymphocytes, Helper-Inducer/pathology | 2 | 6.0 |
Cell Transformation, Viral | 2 | 0.0 |
Membrane Glycoproteins/analysis | 3 | 1.0 |
P-Glycoprotein | 2 | 4.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 3 | 2.0 |
Leukemia, Lymphocytic, Acute/immunology/*pathology | 4 | 44.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/genetics | 3 | 30.0 |
Epithelium/immunology | 2 | 1.0 |
Megakaryocytes/*pathology | 3 | 10.0 |
Antigens, CD/physiology | 3 | 1.0 |
Thymus Gland/*cytology | 2 | 3.0 |
*Gene Expression | 6 | 0.0 |
Immunoblotting | 2 | 0.0 |
Frozen Sections | 2 | 2.0 |
Lymphatic Metastasis | 2 | 0.0 |
*Lymphocyte Subsets | 3 | 3.0 |
Leukemia, Myeloid/drug therapy/*immunology | 2 | 28.0 |
T-Lymphocytes/drug effects | 2 | 3.0 |
Asparaginase/administration & dosage | 2 | 9.0 |
Lymphocytes/immunology | 3 | 0.0 |
Arthritis, Rheumatoid/immunology/*therapy | 4 | 18.0 |
Fetus/*immunology | 3 | 6.0 |
T-Lymphocytes/*immunology/physiology | 2 | 5.0 |
Blast Crisis/genetics/*pathology | 4 | 57.0 |
Leukemia, Myeloid, Chronic/genetics/*pathology | 4 | 30.0 |
Gene Rearrangement/genetics | 2 | 4.0 |
*Ploidies | 3 | 4.0 |
Biotin | 2 | 3.0 |
Tissue Distribution | 2 | 0.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Interferon Type II/genetics | 2 | 2.0 |
Killer Cells, Natural/*metabolism | 2 | 3.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Lymphoproliferative Disorders/*pathology | 2 | 50.0 |
T-Lymphocytes/microbiology | 2 | 8.0 |
Antigens, Differentiation, Myelomonocytic/*biosynthesis | 2 | 13.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Bone Marrow Purging/*methods | 3 | 8.0 |
Lymphoid Tissue/*pathology | 2 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 16 | 6.0 |
Graft Rejection/immunology/*prevention & control | 2 | 10.0 |
Graft Survival | 2 | 0.0 |
T-Lymphocyte Subsets/*cytology | 2 | 7.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 6 | 3.0 |
Receptors, Immunologic/immunology | 2 | 1.0 |
Staining and Labeling | 2 | 0.0 |
Antigens, CD8/*analysis | 2 | 2.0 |
Immunoglobulins, Heavy-Chain/*genetics | 6 | 4.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Antigens, CD28 | 3 | 2.0 |
Antigens, Surface/genetics | 2 | 4.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Macrophages/immunology | 2 | 0.0 |
Tumor Markers, Biological/*analysis/blood | 2 | 10.0 |
*Magnetics | 4 | 16.0 |
*Chromosomes, Human, Pair 21 | 2 | 1.0 |
Antigens, CD/*immunology/metabolism | 2 | 6.0 |
Bromelains/*pharmacology | 2 | 40.0 |
L-Selectin | 3 | 4.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
Antigens, CD57 | 3 | 4.0 |
Down Syndrome/*complications | 3 | 21.0 |
Peroxidase/metabolism | 2 | 1.0 |
Receptors, Fc/*immunology | 2 | 6.0 |
Cytosol/enzymology | 2 | 1.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 2 | 7.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Leukemia, T-Cell, Acute/immunology/*pathology | 3 | 75.0 |
Receptors, Transferrin/analysis | 2 | 5.0 |
Antigens, CD/*genetics | 4 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 5 | 9.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 2 | 8.0 |
Hematopoietic Stem Cells/drug effects/immunology | 2 | 33.0 |
Antigens, CD29 | 2 | 3.0 |
Antigens, CD45 | 8 | 3.0 |
Histocompatibility Antigens/analysis | 4 | 6.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Lymphoma, Lymphoblastic/*pathology | 2 | 50.0 |
Immunologic Techniques | 4 | 1.0 |
*Antibody Specificity | 2 | 2.0 |
*Immunosorbent Techniques | 2 | 11.0 |
Antigens, Surface/*immunology | 4 | 2.0 |
Cross-Linking Reagents | 3 | 0.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
Immunosuppression | 3 | 1.0 |
Hematopoietic Stem Cells/cytology | 3 | 3.0 |
*Immunologic Techniques | 2 | 6.0 |
Leukemia, T-Cell/pathology/surgery/*therapy | 2 | 100.0 |
Tumor Cells, Cultured/pathology | 3 | 5.0 |
Monocytes/pathology | 2 | 5.0 |
Thymus Gland/*embryology | 2 | 50.0 |
Histocompatibility Antigens/*analysis | 2 | 4.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 2 | 2.0 |
Synovial Membrane/immunology | 2 | 6.0 |
Erythrocytes/immunology | 2 | 0.0 |
Lymphoma, T-Cell/immunology/*pathology | 2 | 33.0 |
Neprilysin | 8 | 10.0 |
Antigens, Differentiation/physiology | 2 | 3.0 |
Receptors, IgG | 2 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 2 | 3.0 |
Leukemia/*diagnosis/immunology | 2 | 33.0 |
Hyperplasia | 2 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Receptors, Antigen, T-Cell/*analysis | 5 | 9.0 |
Receptors, Antigen, T-Cell, gamma-delta | 5 | 9.0 |
DNA Nucleotidylexotransferase/*metabolism | 4 | 66.0 |
Lymphocyte Depletion | 3 | 1.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
Gene Rearrangement, T-Lymphocyte/*genetics | 4 | 50.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
T-Lymphocytes/drug effects/*immunology | 3 | 2.0 |
Blast Crisis/*genetics/pathology | 2 | 40.0 |
Antigens, Surface/*genetics | 3 | 4.0 |
Antigens, Thy-1 | 2 | 6.0 |
*Genes, Immunoglobulin | 4 | 2.0 |
Lymph Nodes/immunology/pathology | 2 | 4.0 |
T-Lymphocytes/immunology/*pathology | 4 | 10.0 |
Gene Rearrangement/physiology | 2 | 50.0 |
DNA Nucleotidylexotransferase/metabolism | 2 | 10.0 |
*T-Lymphocytes, Suppressor-Effector | 2 | 25.0 |
Antibodies, Monoclonal/*diagnostic use | 5 | 2.0 |
Rosette Formation | 4 | 1.0 |
*Cloning, Molecular | 2 | 0.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Diglycerides/pharmacology | 2 | 5.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Antigens, CD58 | 2 | 1.0 |
Macaca mulatta | 2 | 0.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Receptors, Immunologic/*immunology | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2.0 |
Lymphoma/*immunology | 2 | 6.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Mitogens/*pharmacology | 2 | 1.0 |
Stem Cells/cytology | 4 | 5.0 |
Hybrid Cells | 2 | 0.0 |
Lymphokines/pharmacology | 2 | 1.0 |
T-Lymphocytes | 10 | 4.0 |
Calibration | 2 | 1.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Egypt | 2 | 4.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Leukemia, Myelocytic, Acute/immunology/pathology | 2 | 28.0 |
Chromosomes, Human, Pair 10 | 2 | 1.0 |
Cell Membrane/immunology | 4 | 1.0 |
Antigens, Differentiation | 4 | 5.0 |
*Gene Rearrangement, T-Lymphocyte | 5 | 10.0 |
Antibodies, Monoclonal/physiology | 2 | 2.0 |
Immunotoxins/*toxicity | 2 | 15.0 |
Recombinant Proteins | 2 | 0.0 |
*Cell Adhesion Molecules | 2 | 0.0 |
Endocytosis | 2 | 0.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Hematopoietic Stem Cells/immunology/*pathology | 2 | 10.0 |
Ammonium Chloride/pharmacology | 2 | 5.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte | 7 | 2.0 |
Lymphocyte Function-Associated Antigen-1 | 2 | 2.0 |
Antibodies, Monoclonal/*physiology | 2 | 5.0 |
Immunotoxins/*pharmacology | 5 | 11.0 |
Leukemia, Lymphocytic/*immunology | 2 | 6.0 |
Receptors, Interleukin-2 | 2 | 1.0 |
Cell Survival/drug effects | 2 | 0.0 |
Antigens, Neoplasm/*genetics | 2 | 3.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Antigens, CD4/*biosynthesis | 3 | 6.0 |
Antigens, CD45/biosynthesis | 2 | 3.0 |
Antigens, CD56/*biosynthesis | 2 | 22.0 |
Antigens, Surface/analysis/*genetics | 2 | 20.0 |
Cell Survival | 2 | 0.0 |
Leukemia, Lymphocytic/*immunology/pathology | 2 | 18.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Clone Cells/pathology | 2 | 3.0 |
